
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
"By using our technique, and really preserving that urethral length really well, it seems to help those patients in particular to have better outcomes," David I. Lee, MD, FACS.
In this video, David I. Lee, MD, FACS, discusses the AUA 2024 abstract, "Extended preservation of the prostatic urethra mitigates the disadvantage of innate short membranous urethral length." Lee is director of the UCI Health Comprehensive Prostate Cancer Program and professor of urology at the UCI School of Medicine.
This transcription was edited for clarity.






